TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10660004

Group type: EXPERIMENTAL
Intervention: Two sessions of individual patient counseling
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Two telephone contacts
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 60 mEq supplemental oral potassium daily
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 8646351

Group type: EXPERIMENTAL
Intervention: Intraperitoneal kanamycin (500 mg)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 69
Study: 1353642

Group type: EXPERIMENTAL
Intervention: High-purity factor VIII concentrate
Number of subjects: 33

Group type: COMPARATOR
Intervention: Intermediate-purity factor VIII concentrate
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study: 6650492

Group type: EXPERIMENTAL
Intervention: DDAVP and intravenous fluids
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo and intravenous fluids
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 8
Study: 30846472

Group type: EXPERIMENTAL
Intervention: Treadmill exercise at 60% of peak oxygen consumption
Number of subjects: 14

Group type: COMPARATOR
Intervention: Resting breathing (control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) therapy
Number of subjects: 14
Study: 29422023

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy delivered by trained and supervised lay health workers (6 sessions)
Number of subjects: 573

Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 573
Study: 27533711

Group type: EXPERIMENTAL
Intervention: C-MAC videolaryngoscope
Number of subjects: 150

Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 150
Study: 25266433

Group type: EXPERIMENTAL
Intervention: Poverty at birth
Number of subjects: 2853

Group type: EXPERIMENTAL
Intervention: Parental education, pre‐ and postnatal growth in length, home stimulation
Number of subjects: 2853

Group type: EXPERIMENTAL
Intervention: Home stimulation
Number of subjects: 2853

Group type: EXPERIMENTAL
Intervention: Growth in the first 2 years
Number of subjects: 2853
Study: 22917555

Group type: EXPERIMENTAL
Intervention: Increased monocyte count (≥800/μl)
Number of subjects: 3717
Study: 19594194

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs) - olanzapine, quetiapine, risperidone, ziprasidone
Number of subjects: 1770

Group type: COMPARATOR
Intervention: First-generation antipsychotic (FGA) - perphenazine
Number of subjects: 1770

Group type: EXPERIMENTAL
Intervention: First-generation antipsychotic (FGA) or second-generation antipsychotic (SGA) in CUtLASS
Number of subjects: 1770
Study: 17475943

Group type: EXPERIMENTAL
Intervention: Prednisolone 60 mg on days 1 and 2, 40 mg on days 3 and 4, and 20 mg on days 5 and 6 (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo tablets for 6 days (Group B)
Number of subjects: 100
Study: 15940035

Group type: EXPERIMENTAL
Intervention: Valganciclovir
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Higher ganciclovir AUC
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Prophylactic exposure to ganciclovir
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Higher ganciclovir exposure
Number of subjects: 240
Study: 12500991

Group type: COMPARATOR
Intervention: Normal diet (N)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fat supplemented diet (F)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (C)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Adjusted normal diet (AN)
Number of subjects: 6
Study: 9583304

Group type: EXPERIMENTAL
Intervention: Whole-body vibration at 10 Hz for 5 minutes
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control period (no vibration)
Number of subjects: 7
Study: 7712671

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 16
Study: 2694509

Group type: EXPERIMENTAL
Intervention: Low dose of mefloquine/sulfadoxine/pyrimethamine (MSP)
Number of subjects: 914

Group type: COMPARATOR
Intervention: Fansidar
Number of subjects: 914
Study: 917333

Group type: EXPERIMENTAL
Intervention: Citiolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30851699

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 9 weeks (specifics not provided)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: PHQ‐9 score at week 0
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Suicidal ideation score at week 0
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: PHQ‐9 total score at week 9
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Severity of side effects at week 9
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: PHQ‐9 score defined as 10 or more at week 25
Number of subjects: 494
Study: 29197871

Group type: EXPERIMENTAL
Intervention: Carvedilol (n=15)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (n=16)
Number of subjects: 72
Study: 25271009

Group type: EXPERIMENTAL
Intervention: Sucralose (24 mg in 200 ml of water)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aspartame (72 mg in 200 ml of water)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water (200 ml)
Number of subjects: 16
Study: 23589672

Group type: EXPERIMENTAL
Intervention: Interleukin-7 (IL-7) administered to virally suppressed subjects
Number of subjects: 0
Study: 21677070

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cetylpyridinium mouthwash
Number of subjects: 120
Study: 19552904

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg, 3 times per day for 2 cycles)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 17926620

Group type: EXPERIMENTAL
Intervention: Acupoint injection of 2000 microg of VitB12
Number of subjects: 104

Group type: COMPARATOR
Intervention: Oral administration of Carbamazepine
Number of subjects: 104
Study: 15529370

Group type: EXPERIMENTAL
Intervention: Alendronate (40 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11574913

Group type: EXPERIMENTAL
Intervention: 6-day dose escalation of TMP-SMZ
Number of subjects: 100

Group type: COMPARATOR
Intervention: Direct rechallenge of TMP-SMZ
Number of subjects: 100
Study: 9623424

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastroplasty
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open gastroplasty
Number of subjects: 30
Study: 7836551

Group type: EXPERIMENTAL
Intervention: co‐trimoxazole 160/800 mg twice a day
Number of subjects: 8

Group type: COMPARATOR
Intervention: no treatment (control)
Number of subjects: 8
Study: 3400846

Group type: EXPERIMENTAL
Intervention: Isoflurane 0.5% in oxygen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (oxygen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitrous oxide in oxygen
Number of subjects: 0
Study: 30394153

Group type: EXPERIMENTAL
Intervention: Class 3 obesity (BMI ≥ 40.0)
Number of subjects: 911

Group type: COMPARATOR
Intervention: Overweight (BMI 25.0-29.9)
Number of subjects: 911
Study: 30878303

Group type: EXPERIMENTAL
Intervention: Extensive transrectal biopsy with anterior sampling (median 19 cores)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Standard transrectal biopsy (median 12 cores)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Extensive transrectal biopsy with anterior sampling
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Postbiopsy infections
Number of subjects: 340
Study: 28380062

Group type: EXPERIMENTAL
Intervention: Normal saline (1700 mL infused)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Gelatine 4% (1500 mL infused)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 6% (1500 mL infused)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Albumin 5% (1500 mL infused)
Number of subjects: 115
Study: 24980216

Group type: EXPERIMENTAL
Intervention: Unilateral VA hypoplasia
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: VA insufficiency
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study: 23454780

Group type: EXPERIMENTAL
Intervention: Visual concept mapping method
Number of subjects: 80

Group type: COMPARATOR
Intervention: Face-to-face method (Control)
Number of subjects: 80
Study: 21458598

Group type: COMPARATOR
Intervention: Low TFA diet (base diet, 34% energy from fat; 0.1% energy from TFA)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Base diet with vaccenic acid (3.0% energy)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Base diet with mixed isomers of TFA from partially hydrogenated vegetable oil (3.0% energy)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Base diet with cis‐9, trans‐11 CLA (1.0% energy)
Number of subjects: 116
Study: 19103321

Group type: EXPERIMENTAL
Intervention: High intensity intervention
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Low intensity intervention
Number of subjects: 379

Group type: COMPARATOR
Intervention: Control
Number of subjects: 379
Study: 17054617

Group type: EXPERIMENTAL
Intervention: Web-based tutorial including the interactive 3-D model
Number of subjects: 28

Group type: COMPARATOR
Intervention: Web-based tutorial without the interactive 3-D model (Control)
Number of subjects: 28
Study: 12743981

Group type: EXPERIMENTAL
Intervention: Pegylated-liposomal doxorubicin (Doxil™) at an initial dose of 55 mg/m2 every four weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Pegylated-liposomal doxorubicin (Doxil™)
Number of subjects: 47
Study: 10893367

Group type: EXPERIMENTAL
Intervention: Rehabilitation group underwent a lower-extremity training program, walking at 70% of maximum speed on the SWT, 1 hour, 6 days/week for 12 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 60
Study: 8882073

Group type: EXPERIMENTAL
Intervention: Low dose (250 micrograms) inhaled terbutaline
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High dose (1000 micrograms) inhaled terbutaline
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1348219

Group type: EXPERIMENTAL
Intervention: Formoterol (4 x 6 micrograms twice a day and as necessary, n = 19)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Salbutamol (4 x 100 micrograms twice a day and as necessary, n = 16)
Number of subjects: 37
Study: 3987793

Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nadolol 160 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg 8 hourly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg with Nifedipine 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29768084

Group type: EXPERIMENTAL
Intervention: Phototherapy (780 nm, 25 J/cm2, 50 mW, 20 sec, and 1 J per point) on three points of the masseter and one point of the anterior temporal muscle on each side.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham group (device switched off, same procedure as laser group).
Number of subjects: 52
Study: 27759409

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Compomer
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Composite resin
Number of subjects: 31
Study: 24725763

Group type: EXPERIMENTAL
Intervention: Combination therapy with atorvastatin (20mg/day) and ezetimibe (10mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy with atorvastatin alone
Number of subjects: 0
Study: 22340556

Group type: EXPERIMENTAL
Intervention: Alginate dressing and mouse epidermal growth factor (mEGF)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: mEGF
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study: 20930431

Group type: EXPERIMENTAL
Intervention: Risedronate (2.5 mg/day) + alfacalcidol (0.25 µg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Alfacalcidol (0.25 µg/day) alone
Number of subjects: 40
Study: 18025881

Group type: EXPERIMENTAL
Intervention: Baseline Metabolic Syndrome (MS) defined by ATP-III criteria
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Baseline Metabolic Syndrome (MS) defined by IDF criteria
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Incident Metabolic Syndrome (MS) defined by ATP-III criteria
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Incident Metabolic Syndrome (MS) defined by IDF criteria
Number of subjects: 881
Study: 15951474

Group type: EXPERIMENTAL
Intervention: Long-acting octreotide 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-acting octreotide 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged-release lanreotide 90 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged-release lanreotide 120 mg
Number of subjects: 0
Study: 12131941

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Dipyrone
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 10325895

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms twice daily plus the run in dose of fluticasone propionate
Number of subjects: 274

Group type: COMPARATOR
Intervention: Doubling the dose of fluticasone propionate (200 or 500 micrograms twice daily)
Number of subjects: 274
Study: 7562165

Group type: EXPERIMENTAL
Intervention: 2% lidocaine jelly
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inactive jelly
Number of subjects: 30
Study: 1778684

Group type: EXPERIMENTAL
Intervention: Cognitive/behavioral intervention plus cardiac counseling (E2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cardiac counseling only (C2)
Number of subjects: 0
Study: 6192562

Group type: EXPERIMENTAL
Intervention: Xenon arc photocoagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 0
Study: 30819358

Group type: EXPERIMENTAL
Intervention: Prasugrel pre-treatment
Number of subjects: 4001
Study: 29746146

Group type: EXPERIMENTAL
Intervention: Fastball
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Changeup
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Curveball
Number of subjects: 20
Study: 26959056

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g per day for six days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (carboxymethyl cellulose)
Number of subjects: 30
Study: 24550580

Group type: COMPARATOR
Intervention: Metformin (1000 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg/day) plus bromocriptine (0.8 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg/day) plus bromocriptine (1.6 mg/day)
Number of subjects: 0
Study: 22106246

Group type: EXPERIMENTAL
Intervention: High-volume fluid therapy (10 mL/kg/h)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Low-volume fluid therapy (4 mL/kg/h)
Number of subjects: 107
Study: 20074867

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 2112

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 2112

Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 2112

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 2112
Study: 17704795

Group type: EXPERIMENTAL
Intervention: Mixed-type exercise, progressive relaxation and psychoeducation programme
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional care group (CC)
Number of subjects: 19
Study: 15797676

Group type: EXPERIMENTAL
Intervention: Olive oil diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sunflower oil diet
Number of subjects: 18
Study: 12499786

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin 200mg IV q 12 hours for 3 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin
Number of subjects: 40
Study: 10338322

Group type: EXPERIMENTAL
Intervention: Leucocyte depletion filter
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control filter
Number of subjects: 40
Study: 7796076

Group type: EXPERIMENTAL
Intervention: Short Synacthen Test (SST)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Insulin Tolerance Test (ITT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Correlation between ITT and SST
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cortisol response correlation
Number of subjects: 22
Study: 2326330

Group type: EXPERIMENTAL
Intervention: Predictable reinforcement schedule (fixed-interval 90-sec)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nonpredictable reinforcement schedule (random-interval 90-sec)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Random reinforcement schedule (nonpredictable)
Number of subjects: 52
Study: 6104788

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 236
Study: 31296300

Group type: EXPERIMENTAL
Intervention: Patients with PAD and diabetes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients without diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Every 1% increase in HbA1c in patients with diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: On-treatment TIMI major bleeding in patients with diabetes
Number of subjects: 0
Study: 27087507

Group type: EXPERIMENTAL
Intervention: Propiverine ER 30 mg
Number of subjects: 324

Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg
Number of subjects: 324
Study: 26445092

Group type: EXPERIMENTAL
Intervention: Behavioural intervention to reduce formula-milk intake, promote responsive feeding and healthy weaning, delivered over 6 months through three face-to-face contacts, two telephone contacts, and written materials.
Number of subjects: 650

Group type: COMPARATOR
Intervention: Control group receiving the same number of contacts discussing general feeding issues.
Number of subjects: 650
Study: 23351597

Group type: EXPERIMENTAL
Intervention: Test formulation (capsule) of levodropropizine 60 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Reference formulation (syrup) of levodropropizine 60 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both formulations (capsule and syrup)
Number of subjects: 36
Study: 20680012

Group type: EXPERIMENTAL
Intervention: Motivation-focused maintenance program
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Skill-based maintenance approach
Number of subjects: 338

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 338
Study: 19750832

Group type: EXPERIMENTAL
Intervention: Contact technique (48 eyes)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Immersion technique (63 eyes)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 111
Study: 16924006

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) ultrasonography
Number of subjects: 112

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 112
Study: 11057790

Group type: COMPARATOR
Intervention: Survanta (100 mg/kg) - 0 doses
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Survanta (100 mg/kg) - 1 dose
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Survanta (100 mg/kg) - 2 doses
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Survanta (100 mg/kg) - 3 doses
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Prenatal corticosteroid treatment
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Presence of patent ductus arteriosus
Number of subjects: 27
Study: 8649872

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients (I)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Chronic sinusitis patients without cystic fibrosis (C)
Number of subjects: 70
Study: 2000045

Group type: EXPERIMENTAL
Intervention: methionyl recombinant human growth hormone (met‐hGH) 0.06 IU/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 12
Study: 6393665

Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nation-wide study
Number of subjects: 0
Study: 31490424

Group type: EXPERIMENTAL
Intervention: 100 mg CAF + 100 mg CA
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31248711

Group type: EXPERIMENTAL
Intervention: Unrestricted sleeping position
Number of subjects: 408

Group type: COMPARATOR
Intervention: Restricted sleeping position
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 408
Study: 29310688

Group type: EXPERIMENTAL
Intervention: 2 g/day EPA/DHA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 g/day EPA/DHA
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EPA/DHA therapy
Number of subjects: 0
Study: 27305950

Group type: EXPERIMENTAL
Intervention: Tailor-made lifestyle intervention (diet and exercise) lasting 2.5 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailor-made lifestyle intervention (diet and exercise)
Number of subjects: 0
Study: 25440805

Group type: EXPERIMENTAL
Intervention: Routine early invasive strategy
Number of subjects: 2974

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 2974
Study: 22214903

Group type: EXPERIMENTAL
Intervention: Zolpidem (GABARα1-selective agonist)
Number of subjects: 0
Study: 20588058

Group type: EXPERIMENTAL
Intervention: losartan 100 mg/day
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: candesartan 12 mg/day
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: olmesartan 40 mg/day
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg/day
Number of subjects: 68
Study: 16887213

Group type: EXPERIMENTAL
Intervention: Patients with atrial fibrillation
Number of subjects: 3059

Group type: EXPERIMENTAL
Intervention: Patients with a diagnosis of hypertension
Number of subjects: 3059
Study: 16240208

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261